make the call.

Ask Canada’s health ministers to act on access to daraxonrasib, a new treatment for pancreatic cancer.

Start with step 1

Since August, patients in the United States have had a new treatment for pancreatic cancer. In Canada, there is still no decision and no public timeline.

United States
Approved by the Food and Drug Administration on August 26, 2026.
European Union
Approved by the European Commission in November 2026.
Canada
Not approved. No decision, and no public timeline.
The company
When we asked on November 5, 2026, Revolution Medicines gave us no date for filing with Health Canada. Read their reply
The details and sources

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic adenocarcinoma who have already had at least one treatment, or who cannot have combination chemotherapy.

In the clinical trial, median overall survival was 13.2 months for people who took daraxonrasib and 6.7 months for people on standard chemotherapy. Median means half lived longer than this and half did not.

In Canada, daraxonrasib is not approved. The FDA’s published review says it worked with Health Canada on the U.S. review through Project Orbis, a program that lets countries review cancer medicines together. We have not been able to confirm whether an application has been filed in Canada. Daraxonrasib is not on Health Canada’s public list of submissions under review, which is current to September 30, 2026.

Daraxonrasib is a treatment, not a cure, and it is not right for everyone. This page is general information, not medical advice. We are not recommending daraxonrasib or any treatment. Whether it is an option for you is a conversation to have with your care team. Sources: FDA approval announcement, August 26, 2026; European Commission approval, November 2026; FDA review documents for daraxonrasib; Health Canada’s list of submissions under review. Last checked November 20, 2026.

So we’re asking Canadians to pick up the phone.

Offices notice when the phone keeps ringing about the same thing. We connect you to a health minister’s office and give you the words.

what we are asking

The federal Minister of Health
Name one person to lead on Canadian access to daraxonrasib, and work with the company and with the provinces and territories. Tell Canadians what the federal government can do, and what it will do next.
Your province or territory
Name one person to lead on daraxonrasib where you live. Say whether interim or exceptional funding could be considered for eligible patients whose oncologist supports treatment.
Revolution Medicines
Say publicly whether it has applied to Health Canada for approval of daraxonrasib. If it has not, apply, and tell Canadians the date.

how the call works

Step 1: choose who you call

Revolution MedicinesCalling option not yet availableThe company that makes daraxonrasib. It chooses when to apply to Health Canada. We have asked where Canadians should direct their calls.
Why this officeHealth Canada reviews new medicines once a company applies. The Minister can tell Canadians where daraxonrasib stands and bring every government to the same table.

Step 2: read your message

You are callingThe office of the federal Minister of Health

Use your own words if you like. Leaving a voicemail? The same message works, and it still counts.

If the person who answers is unsure where to send you: “This is a public policy message, not a request about one patient’s treatment. Could you please pass it to the Minister’s office?”

Step 3: make the call

Prefer to write? We are confirming this office’s email address and will add it here.

Good to know
  • We count that a call was made and which office it reached. We do not record or listen to your call.
  • The office sees our number, not yours.
  • Please do not share medical records, health card numbers or another person’s health information.
How the line works and what we keep

Made your call? Make it count twice.

Ask one person to call

The message is already written for you.

  • Tell us why it matters to you

    Leave a voice message of up to one minute. We’ll offer this before we connect your call. You can also call 1-855-754-5045, press 1, then press 4.

    This is the only thing we record. We ask your permission before sharing it, and you can change your mind at any time.

  • Get campaign updates by text

    Text JOIN to (855) 754-5045

    The Heather Cutler Foundation will text you updates about this campaign, no more than two a month, and only when something changes. Reply STOP at any time. Message and data rates may apply.

    Text JOIN

in their own words

Why people are calling

Shared with each person’s permission. You can record your own when you call, up to one minute.

why the wait

Four things have to happen before a public drug plan in Canada pays for a new cancer treatment. Here is where daraxonrasib stands on each.

  1. 1 · The company

    Revolution Medicines asks Health Canada to approve daraxonrasib.Now: not confirmed. The company has given no filing date.

  2. 2 · Health Canada

    Health Canada reviews the evidence and decides whether the drug can be sold here.Now: no decision.

  3. 3 · Funding review

    Canada’s Drug Agency, and INESSS in Quebec, advise public drug plans on whether to pay. The plans then negotiate a price together.Now: still ahead.

  4. 4 · Your province

    Each province and territory decides whether its own drug plan will cover it.Now: still ahead.

That is why the call goes to two offices. The federal Minister can tell Canadians where the first two steps stand. Your province or territory can get ready for the last two now, so that funding does not add another delay.

We stand with every patient fighting for the chance to fight.

Questions people ask

Is my call recorded?

No. We count that a call was made and which office it reached. The only recording is the voice message you may choose to leave for us.

What if nobody answers?

Leave a voicemail using the same words. Offices are usually staffed on weekdays during business hours in their own time zone.

I have never called a minister’s office. What happens?

A staff member answers, listens, and takes a note. They take calls like this every day. You do not need to know the details of drug policy. Your name, where you live and the ask are enough.

I cannot make a phone call. Can I still take part?

Yes. Choose an office above, then use “Write instead”. It opens a ready-made message in your own email.

Who is behind this campaign?

The Heather Cutler Foundation, a registered Canadian charity based in Newfoundland and Labrador, with Pancreatic Cancer Can’t Wait, a patient-led campaign.

our partners

This campaign is built with Salman Syed, who runs Pancreatic Cancer Can’t Wait. Does your organization want to stand with it? See how to endorse, or email support@heathercutler.ca.